Antitumor Activity of Crizotinib in Lung Cancers Harboring a MET Exon 14 Alteration

MET exon 14 alterations are oncogenic drivers of non-small cell lung cancers (NSCLCs).(1) These alterations are associated with increased MET activity and preclinical sensitivity to MET inhibition.(2) Crizotinib is a multikinase inhibitor with potent activity against MET.(3) The antitumor activity a...

Descripción completa

Detalles Bibliográficos
Autores principales: Drilon, Alexander, Clark, Jeffrey W., Weiss, Jared, Ou, Sai-Hong Ignatius, Camidge, D. Ross, Solomon, Benjamin J., Otterson, Gregory A., Villaruz, Liza C., Riely, Gregory J., Heist, Rebecca S., Awad, Mark M., Shapiro, Geoffrey I., Satouchi, Miyako, Hida, Toyoaki, Hayashi, Hidetoshi, Murphy, Danielle A., Wang, Sherry C., Li, Sherry, Usari, Tiziana, Wilner, Keith D., Paik, Paul K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8500676/
https://www.ncbi.nlm.nih.gov/pubmed/31932802
http://dx.doi.org/10.1038/s41591-019-0716-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8500676/
https://www.ncbi.nlm.nih.gov/pubmed/31932802
http://dx.doi.org/10.1038/s41591-019-0716-8

Ejemplares similares